北大医药：拟收购大新药业9.75%股权

Group 1 - The company plans to acquire a 9.75% stake in Daxin Pharmaceutical for no more than 22.6688 million yuan [1] - Upon completion of the transaction, the company will hold a 9.75% equity interest in Daxin Pharmaceutical [1] - This transaction is classified as a related party transaction but does not constitute a major asset reorganization [1] Group 2 - Daxin Pharmaceutical is a key high-tech enterprise under the National Torch Program, primarily engaged in the research and production of active pharmaceutical ingredients and intermediates [1] - The company’s product range includes nutritional drugs, lipid-regulating agents, and antibiotics, and it also engages in CDMO (Contract Development and Manufacturing Organization) collaboration [1]